Low-dose Administration of Carperitide for Acute Heart Failure: the LASCAR-AHF study
The Japanese multicentre LASCAR-AHF study showed that in patients with acute heart failure, low-dose carperitide added to standard therapy did not reduce all-cause mortality/hospitalization for heart failure at 2 years compared with standard therapy, according to a study reported by Dr. Toshiyuki Nagai of Hokkaido University, in the Late Breaking Clinical Trials Session at Heart Failure 2024.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
